- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05135858
Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma (METHOGLU)
Dose Dense Re-challenge of High Dose Methotrexate (HD-MTX) With Glucarpidase (CPG2) for Relapsed Primary Central Nervous System Lymphoma (PCNSL): A Phase I Trial
High dose intravenous Methotrexate (HD-MTX) is the key drug in the treatment of primary central nervous system lymphoma (PCNSL). HD-MTX is usually delivered with time interval ranging from 10 to 21 days. Reduction of injection time interval is limited by MTX renal excretion and systemic toxicity.
Glucarpidase (CPG2) is a recombinant bacterial rescue enzyme that cleaves circulating MTX into inactive metabolites, reducing plasma MTX concentrations within few minutes.
The research hypothesis is that CPG2 used after HD-MTX injection allows to reduce time interval between MTX injections, increase dose intensity of the chemotherapy, reduce systemic toxicity and duration of hospitalization.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Open-label multicenter Phase I dose finding trial based on 3+3 escalation design. The phase I will follow a standard "3+3" dose level escalation design with reduced time interval of HD-MTX injections at fixed dose of HD-MTX to establish the minimum tolerated time interval.
HD-MTX (methotrexate) is administered intravenously at the dose 3.5 g/m² (body surface area capped at 2 m2) over 2 to 3 hours, followed at H24 by glucarpidase with a 3 different MTX administration intervals: 8 days, 6 days, and 5 days.
Treatments will be continued for a maximum of 6 injections until disease progression, unacceptable toxicity, or investigator's/patient's decision.
Three dose levels could be explored under toxicity restrictions, where the dose combination for each cohort of three subjects will be determined by 3+3 escalation rule. Three schedule dose levels will be : every 8 days, every 6 days and every 5 days.
The starting schedule dose of HD-MTX will be one administration of HD-MTX every 8 days for 6 injections.
Dose of MTX will be fixed and will not be modified. No skipping of the dose level will be allowed. No intra-patient dose escalation is allowed.
The DLT evaluation period begins with the first dose of methotrexate and ends at the beginning of the 25th day after the first MTX infusion.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Caroline HOUILLIER, MD
- Phone Number: 01 42 16 41 60
- Email: caroline.houillier@aphp.fr
Study Contact Backup
- Name: Khê HOANG-XUAN, MD,PhD
- Phone Number: 01 42 16 03 81
- Email: khe.hoang-xuan@aphp.fr
Study Locations
-
-
-
Paris, France, 75013
- Recruiting
- Hôpital Pitié-Salpétrière
-
Principal Investigator:
- Caroline HOUILLIER, MD
-
Contact:
- Caroline HOUILLIER, MD
- Phone Number: 01 42 16 41 60
- Email: caroline.houillier@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Cerebral relapse of primary CNS lymphoma (any line)
- Pathological diagnosis of diffuse large B cell lymphoma (or cytological diagnosis in the CSF or in the vitreous) at initial diagnosis (not mandatory at the time of the present relapse)
- Absence of any systemic involvement confirmed by full body CT scan and/or FDG-PET scan
- Age≥18 years
- HD-MTX based chemotherapy in first line treatment, with complete response lasting at least 6 months after the end of the 1st line treatment
- No administration of other anticancer therapy within the 3 weeks prior to inclusion
- Karnofsky performance status (KPS) ≥ 50
Adequate haematological, renal and hepatic function (adequate Laboratory Parameters within 21 days):
- Absolute neutrophil count (ANC) >1000/mm3
- Platelets > 100,000/mm3 independent of transfusion support
- Alanine aminotransferase and aspartate aminotransferase ≤ 3 x upper limit of normal (ULN) and/or total bilirubin ≤ 1,5x ULN, unless related to Gilbert's or Meulengracht disease
- Estimated Glomerular Filtration Rate ≥ 60 mL/min/1.73m2) (MDRD)
- All non-hematological adverse events (AEs) related to prior therapy completely resolved or improved to Grade 1-2 (except for alopecia or fatigue).
- Written informed consent, which could be signed by the trustworthy person or close relatives in case the neurologic status of the patient does not allow him to sign. In case the patient is unable to sign the consent at baseline, but his neurological status improves during the treatment, he will be asked to give his written informed "follow-up" consent
Exclusion Criteria:
- Positive HIV serology
- Active viral infection with Hepatitis B or C virus
- Preexisting immunodeficiency (organ transplant recipient)
- Relevant congestive heart failure interfering with hydration
- Isolated CNS relapse of systemic non-Hodgkin's lymphoma (NHL)
- Pregnancy or lactation. An effective contraception is mandatory for patients (men and women of childbearing potential) all along the study participation and during at least 6 months after the end of MTX. Men must not donate sperm all along the study participation and during at least 6 months after the end of MTX.
- Third space (i.e. pleural effusion, ascites, extended oedema).
- Obesity (body mass index >30 kg/m2).
- Any other active malignancy, except basocellular carcinoma and non-invasive cervix cancer
- Absolute contraindication to MTX or leucovorin
- Previous use of carboxypeptidase for delayed MTX excretion and kidney dysfunction after HD-MTX
- No social security affiliation
- Persons under legal protection (tutorship or curatorship) or safety measure
- Participation in any other clinical trial (Jardé 1 and 2) either 1 month prior to or during this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CPG2
6 infusions of glucarpidase
|
Glucarpidase (CPG2) Dose: 2000 U (2 vials of 1000 U per dose) 5 minutes-intravenous administration 24 hours after each Methotrexate infusion (i.e. 6 times in the whole protocol)
MTX will be administred 6 times during the protocol, at a variable interval of 8, 6 or 5 days.
It will be administrated in a 2 to 3-hour IV infusion, at the dose of 3.5 g/m2 (body surface area capped at 2 m2).
Each MTX administration will be preceded by a prehydration and will be followed by a posthydration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The occurrence of a dose schedule limiting toxicity (DLT)
Time Frame: 25th day after the first injection of methotrexate
|
defined as any of the following events assessed as related or possibly related to methotrexate:
|
25th day after the first injection of methotrexate
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency and grading of adverse event according to NCI-CTCAE v5.0
Time Frame: through study completion, an average of 4 months
|
through study completion, an average of 4 months
|
|
Mean score of neurocognition assessed by neuropsychological testing at baseline and within the - Neurocognition assessed by neuropsychological testing at baseline and within the 3 months after the end of HD-MTX treatment
Time Frame: 3 months after the end of HD-MTX treatment
|
3 months after the end of HD-MTX treatment
|
|
Overall response rate according to IPCG criteria
Time Frame: After 3 cycles (each cycle is 5, 6 or 8 days), at the end of treatment (up to 48 days) and at 3 months after the end of treatment (up to 48 days)
|
After 3 cycles (each cycle is 5, 6 or 8 days), at the end of treatment (up to 48 days) and at 3 months after the end of treatment (up to 48 days)
|
|
Mean of dosages of MTX and its metabolites in the blood, urine and cerebrospinal fluid (CSF)
Time Frame: At the first and the third cycles (each cycle is 5, 6 or 8 days)
|
At the first and the third cycles (each cycle is 5, 6 or 8 days)
|
|
Mean of dosage of anti-glucarpidase antibodies
Time Frame: At baseline, then prior to each CPG2 dose, at the end of HD-MTX treatment (up to 48 days) and at 3 months after the end of HD-MTX treatment.(up to 48 days)
|
At baseline, then prior to each CPG2 dose, at the end of HD-MTX treatment (up to 48 days) and at 3 months after the end of HD-MTX treatment.(up to 48 days)
|
|
Mean global score of quality of life assessment measured with EORTC QLQ-C30 scale
Time Frame: At baseline, at the end of HD-MTX treatment (up to 48 days) and at 3 months after the end of HD-MTX treatment (up to 48 days)]
|
At baseline, at the end of HD-MTX treatment (up to 48 days) and at 3 months after the end of HD-MTX treatment (up to 48 days)]
|
|
Mean global score of quality of life assessment measured with Brain Module (BM 20)
Time Frame: At baseline, at the end of HD-MTX treatment (up to 48 days) and at 3 months after the end of HD-MTX treatment (up to 48 days)
|
At baseline, at the end of HD-MTX treatment (up to 48 days) and at 3 months after the end of HD-MTX treatment (up to 48 days)
|
|
Median duration of treatment-related hospitalization in acute care unit
Time Frame: From day 1 until discharge from hospital, an average of 4 to 7 weeks
|
Defined as the cumulative time from start of the HD MTX protocol (including the pre-hydration) to its elimination
|
From day 1 until discharge from hospital, an average of 4 to 7 weeks
|
Mean of dosage of CSF IL-10
Time Frame: At baseline and at the end of the treatment (up to 48 days)
|
At baseline and at the end of the treatment (up to 48 days)
|
|
Median duration of hospitalization during the treatment
Time Frame: From day 1 until end of the treatment (up to 48 days)
|
Duration of treatment-related hospitalization in acute care unit
|
From day 1 until end of the treatment (up to 48 days)
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Methotrexate
Other Study ID Numbers
- APHP201186
- 2021-000210-42 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients.
Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Central Nervous System Lymphoma
-
Memorial Sloan Kettering Cancer CenterBristol-Myers SquibbActive, not recruitingPrimary Central Nervous System Lymphoma (PCNSL)United States
-
Ono Pharmaceutical Co. LtdRecruitingPrimary CNS Lymphoma | Refractory Primary Central Nervous System LymphomaUnited States
-
Second Affiliated Hospital, School of Medicine,...Active, not recruitingPrimary Central Nervous System Lymphoma | Refractory Central Nervous System Lymphoma | Relapsed Primary Central Nervous System LymphomaChina
-
National Taiwan University HospitalNot yet recruitingPrimary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; China Medical University Hospital; Chang... and other collaboratorsNot yet recruitingPrimary Central Nervous System Lymphoma (PCNSL)
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingPrimary Central Nervous System Lymphoma (PCNSL)France
-
Curis, Inc.RecruitingRelapsed Primary Central Nervous System Lymphoma | Refractory Hematologic Malignancy | Relapsed Hematologic Malignancy | Refractory Primary Central Nervous System LymphomaUnited States, Spain, France, Czechia, Israel, Italy, Poland
-
Memorial Sloan Kettering Cancer CenterPharmacyclics LLC.Active, not recruitingPrimary Central Nervous System Lymphoma (PCNSL) | Secondary Central Nervous System Lymphoma (SCNSL)United States
-
The First Affiliated Hospital with Nanjing Medical...RecruitingRelapsed or Refractory (R/R) Primary Central Nervous System LymphomaChina
-
James RubensteinIncyte CorporationRecruitingPrimary Central Nervous System Lymphoma | CNS Lymphoma | Secondary Central Nervous System LymphomaUnited States
Clinical Trials on Glucarpidase
-
Fox Chase Cancer CenterSuspended
-
National Cancer Institute (NCI)Children's Oncology GroupCompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | NeurotoxicityUnited States, Canada, Australia, Switzerland
-
Nordic Society for Pediatric Hematology and OncologyLund University HospitalCompletedAcute Lymphoblastic Leukemia (ALL)Finland, Denmark, Iceland, Norway, Sweden
-
BTG International Inc.Completed
-
M.D. Anderson Cancer CenterBTG International Inc.Terminated
-
BTG International Inc.CTI Clinical Trial and Consulting ServicesApproved for marketing
-
Fundacion CRIS de Investigación para Vencer el...BTG International Inc.; BioClever 2005 S.L.; Eurofins ADME, S.L.; NTShub, S.L.RecruitingDiffuse Large B-Cell Lymphoma | Drug ToxicitySpain
-
BTG International Inc.M.D. Anderson Cancer CenterTerminated
-
OHSU Knight Cancer InstituteOregon Health and Science University; BTG International Inc.Recruiting
-
Protherics Medicines Development LimitedResonance IncRecruitingAcute Kidney Injury | Drug ToxicitySpain, France, Italy